Search Results - "Bordogna, W"

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study by Mok, T., Camidge, D.R., Gadgeel, S.M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Pérol, M., Ou, S.-H.I., Ahn, J.S., Shaw, A.T., Bordogna, W., Smoljanović, V., Hilton, M., Ruf, T., Noé, J., Peters, S.

“…•Investigator-assessed PFS data in the ALEX study are now mature (53% of events in the alectinib arm).•Alectinib significantly prolonged PFS vs crizotinib…”
Get full text

3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC) by Barlesi, F, Dingemans, A.M.C, Ou, I, Ahn, J.S, Petris, L.D, Kim, D.W, Yang, J.C.H, Hughes, B, Lena, H, Moro-Sibilot, D, Bearz, A, Viteri, S, Mekhail, T, Spira, A, Zeaiter, A, Bordogna, W, Sturm, C, Golding, S, Morcos, P.N, Govindan, R

Get full text

110P Characteristics and survival outcomes of patients (pts) with RET fusion-positive (RET-fp) solid tumours receiving non-RET inhibitor (RETi) therapy in a real-world setting by Garrido Lopez, P., Siena, S., Taylor, M., Beringer, A., Bordogna, W., Fajardo, O., Nikolaidis, C.

Get full text

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study by Ou, Sai-Hong Ignatius, Ahn, Jin Seok, De Petris, Luigi, Govindan, Ramaswamy, Yang, James Chih-Hsin, Hughes, Brett, Lena, Hervé, Moro-Sibilot, Denis, Bearz, Alessandra, Ramirez, Santiago Viteri, Mekhail, Tarek, Spira, Alexander, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N, Monnet, Annabelle, Zeaiter, Ali, Kim, Dong-Wan

“…Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer…”
Get full text

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer by Gadgeel, Shirish M, Shaw, Alice T, Govindan, Ramaswamy, Gandhi, Leena, Socinski, Mark A, Camidge, D Ross, De Petris, Luigi, Kim, Dong-Wan, Chiappori, Alberto, Moro-Sibilot, Denis L, Duruisseaux, Michael, Crino, Lucio, De Pas, Tommaso, Dansin, Eric, Tessmer, Antje, Yang, James Chih-Hsin, Han, Ji-Youn, Bordogna, Walter, Golding, Sophie, Zeaiter, Ali, Ou, Sai-Hong Ignatius

“…Purpose Alectinib has shown activity in the CNS in phase I and II studies. To further evaluate this activity, we pooled efficacy and safety data from two…”
Get full text

390P Entrectinib in Japanese patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours by Murakami, H., Ohe, Y., Hayashi, H., Esaki, T., Yamaguchi, T., Fukuhara, T., Daga, H., Tanaka, H., Kozuki, T., Osborne, S., Bordogna, W., Goto, K.

Get full text

SO-32 Entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis by Garrido-Laguna, I., Lonardi, S., Bazhenova, L., Peeters, M., Longo, F., Sigal, D., Conkling, P., Duffaud, F., Klingbiel, D., Bordogna, W., Ciardiello, F.

Get full text

666P Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours by Lu, S., De Braud, F.G.M., Fan, Y., Hu, X., Ohe, Y., Yu, Y., Ahn, M-J., Cassier, P., Lin, J.J., Paz-Ares, L., Xue, C., Bordogna, W., Patel, S., Zeuner, H., Dong, X.

Get full text

LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC) by Solomon, B.J., Ahn, J.S., Dziadziuszko, R., Barlesi, F., Nishio, M., Lee, D.H., Lee, J-S., Zhong, W-Z., Horinouchi, H., Mao, W., Hochmair, M.J., de Marinis, F., Migliorino, M.R., Bondarenko, I., Lohmann, T.O., Xu, T., Cardona Gavaldon, A., Bordogna, W., Ruf, T., Wu, Y-L.

Get full text

Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC by Mok, T.S.K., Shaw, A.T., Camidge, R.D., Gadgeel, S.M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Perol, M., Ou, S.-H., Bordogna, W., Smoljanović, V., Hilton, M., Peters, S.

Get full text

1484PD - Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC by Mok, T.S.K., Shaw, A.T., Camidge, R.D., Gadgeel, S.M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Perol, M., Ou, S.-H., Bordogna, W., Smoljanović, V., Hilton, M., Peters, S.

“…We report mature PFS, updated OS and safety data from the global phase III ALEX study (NCT02075840) of ALC vs CRZ in patients (pts) with untreated ALK+ NSCLC…”
Get full text

Retrospective indirect comparison of alectinib phase II data vs ceritinib real-world data in ALK+ NSCLC after progression on crizotinib by Davies, J., Martinec, M., Martina, R., Delmar, P., Coudert, M., Bordogna, W., Golding, S., Crane, G.

Get full text

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer by Yang, James Chih-Hsin, Ou, Sai-Hong Ignatius, De Petris, Luigi, Gadgeel, Shirish, Gandhi, Leena, Kim, Dong-Wan, Barlesi, Fabrice, Govindan, Ramaswamy, Dingemans, Anne-Marie C, Crino, Lucio, Lena, Herve, Popat, Sanjay, Ahn, Jin Seok, Dansin, Eric, Golding, Sophie, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N, Zeaiter, Ali, Shaw, Alice T

“…Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and…”
Get more information

1484PDFinal PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC by Mok, T S K, Shaw, A T, Camidge, R D, Gadgeel, S M, Rosell, R, Dziadziuszko, R, Kim, D-W, Perol, M, Ou, S-H, Bordogna, W, Smoljanović, V, Hilton, M, Peters, S

“…Abstract Background We report mature PFS, updated OS and safety data from the global phase III ALEX study (NCT02075840) of ALC vs CRZ in patients (pts) with…”
Get full text

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer by Ou, Sai-Hong Ignatius, Gadgeel, Shirish M., Barlesi, Fabrice, Yang, James Chih-Hsin, De Petris, Luigi, Kim, Dong-Wan, Govindan, Ramaswamy, Dingemans, Anne-Marie, Crino, Lucio, Léna, Hervé, Popat, Sanjay, Ahn, Jin Seok, Dansin, Eric, Mitry, Emmanuel, Müller, Barbara, Bordogna, Walter, Balas, Bogdana, Morcos, Peter N., Shaw, Alice T.

“…•Pooled OS/safety data from the pivotal phase II studies of alectinib in ALK+ NSCLC.•Alectinib demonstrated a final pooled median OS of 29.1 months (95% CI…”
Get full text

Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC) by Barlesi, F., Dingemans, A.-M.C., Yang, J.C.-H., Ou, S.-H.I., Ahn, J.S., De Petris, L., Hughes, B., Lena, H., Bordogna, W., Golding, S., Morcos, P.N., Balas, B., Zeaiter, A., Kim, D.-W.

Get full text

Clinical Drug–Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib by Morcos, Peter N., Cleary, Yumi, Guerini, Elena, Dall, Georgina, Bogman, Katrijn, Petris, Luigi, Viteri, Santiago, Bordogna, Walter, Yu, Li, Martin‐Facklam, Meret, Phipps, Alex

“…The efficacy and safety of alectinib, a central nervous system–active and selective anaplastic lymphoma kinase (ALK) inhibitor, has been demonstrated in…”
Get full text

Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor α-Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell Lines by ALAO, John Patrick, LAM, Eric W.-F, ALI, Simak, BULUWELA, Laki, BORDOGNA, Walter, LOCKEY, Peter, VARSHOCHI, Rana, STAVROPOULOU, Alexandra V, COOMBES, R. Charles, VIGUSHIN, David M

“…Purpose: Estrogen receptor α (ERα)-positive breast cancer cell lines are up to 10 times more sensitive than ERα-negative cell lines to the antiproliferative…”
Get full text

CLINICAL DRUG-DRUG INTERACTIONS (DDIS) THROUGH CYTOCHROME P450 3A (CYP3A) FOR ALECTINIB, A HIGHLY SELECTIVE ALK INHIBITOR by Morcos, PN, Cleary, Y, Dall, G, Guerini, E, Bogman, K, De Petris, L, Ramirez, SV, Bordogna, W, Yu, L, Martin-Facklam, M, Phipps, A

Get full text

Analyses of plasma cytokine/angiogenic factors (C/AFs) profile during preoperative treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer by Nikolinakos, P., Altorki, N., Guarino, M., Tran, H., Rajagopalan, D., Swann, S., Bordogna, W., Ottesen, L., Yankelevitz, D., Heymach, J. V.

“…Abstract only…”
Get full text